Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 10, 2003, Pages 1295-1305

  Chanalaris, A ^a   Lawrence, K M ^a   Stephanou, A ^a   Knight, R D ^b   Hsu, S Y ^c   Hsueh, A J W ^c   Latchman, D S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cell death; Corticotropin releasing factor; MAPK p42 44; Myocardial Ischaemia Reperfusion; PI3K; Protein Kinase B Akt; Stresscopin; Stresscopin related peptide; Urocortin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DOCKING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPTIDE; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; STRESSCOPIN RELATED PEPTIDE; UNCLASSIFIED DRUG; UROCORTIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEART MUSCLE CELL; HEART PROTECTION; HYPOXIA; NEWBORN; NICK END LABELING; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REDUCTION; REOXYGENATION; STRESS;

EID: 0141457760     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00244-X     Document Type: Article

References (53)

1. Lovejoy D.A., Balment R.J. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates. Gen Comp Endocrinol. 115:1999;1-22.
2. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA. 98:2001;2843-2848.
3. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 98:2001;7570-7575.
4. Hsu Y.S., Hsueh A.J.W. Human stresscopin and stress related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat M. 7:2001;605-611.
5. Skelton K.H., Owens M.J., Nemeroff C.B. The neurobiology of urocortin. Regul Peptides. 93:2000;85-92.
6. Nishikimi T., Miyata A., Horio T., Yoshihara F., Nagaya N., Takishita S., et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol. 279:2000; H3031-H3039.
7. Parkes D.G., May C.N. Urocortin: a novel player in cardiac control. New Physiol Sci. 15:2000;264-268.
8. Parkes D.G., Weisinger R.S., May C.N. Cardiovascular actions of CRH and urocortin: an update. Peptides. 22:2001;821-827.
9. Terui K., Higashiyama A., Horiba N., Furukawa K.I., Motomura S., Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol. 169:2001;177-183.
10. Kihara N., Fujimura M., Yamamoto I., Itoh E., Inui A., Fujimiya M. Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor activity in conscious rats. Am J Physiol Gastrointest Liver Physiol. 280:2001;G406-G419.
11. Okamoto S., Kimura K., Saito M. Anorectic effect of leptin is mediated by hypothalamic corticotropin-releasing hormone, but not by urocortin, in rats. Neurosci Lett. 307:2001;179-182.
12. Shade R.E., Blair-West J.R., Carey K.D., Madden L.J., Weisinger R.S., Rivier J.E., et al. Ingestive responses to administration of stress hormones in baboons. Am J Physiol Regul Integr Comp Physiol. 282:2002;R10-R18.
13. Kohno M., Kawahito Y., Tsubouchi Y., Hashiramoto A., Yamada R., Inoue K.I., et al. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab. 86:2001;4344-4352.
14. Radulovic M., Spiess J. Immunomodulatory role of the corticotropin-releasing factor. Arch Immunol Ther Exp (Warsz). 49:2001;33-38.
15. q-proteins. Mol Endocrinol. 14:2000;2076-2091.
16. Kostich W.A., Chen A., Sperle K., Largent B.L. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol. 12:1998;1077-1085.
17. Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci. 885:1999;312-328.
18. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292.
19. Smith G.W., Aubury J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., et al. Corticotropin releasing factor receptor 1-defficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102.
20. Tazi A., Dantzer R., Le Moal M., Rivier J., Vale W., Koob G.F. Corticortropin-releasing factor antagonist blocks stress-induced fighting in rats. Regul Peptide. 18:1987;37-42.
21. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet. 24:2000;415-419.
22. Bale T.L., Contarino A., Smith G.W., et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet. 24:2000;410-414.
23. Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet. 24:2000;403-409.
24. Brar B.K., Stephanou A., Okosi A., Lawrence K.M., Knight R.A., Marber M.S., et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol. 158:1999;55-63.
25. Brar B.K., Jonassen A.K., Stephanou A., Santilli G., Railson J., Knight R.A., et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem. 275:2000;8508-8514.
26. Okosi A., Brar B.K., Chan M., D'Souza L., Smith E., Stephanou A., et al. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides. 32:1998;167-171.
27. Latchman D.S. Urocortin protects against ischemic injury via a MAPK-dependent pathway. Trend Cardiovasc M. 11:2001;167-169.
28. Brar B.K., Railson J., Stephanou A., Knight R.A., Latchman D.S. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol. 172:2002;283-293.
29. Latchman D.S. Urocortin. Int J Biochem Cell Biol. 34:2002;907-910.
30. Simpson P., Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res. 50:1982;101-116.
31. Lavoie J.N., L' Allemain G., Brunet A., Müller R., Pouysségur J. Cyclin D1 expression is regulated positively by the p42/44 MAPK and negatively by the p38/HOG MAPK pathway. J Biol Chem. 271:1996;20608-20616.
32. Kotani K., Ogawa W., Hino Y., Kitamura T., Ueno H., Sano W., et al. Dominant negative forms of Akt (protein kinase B) and atypical protein kinase Cλ do not prevent insulin inhibition of phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem. 274:1999;21305-21312.
33. Pandey P., Avraham S., Kumar S., Nakazawa A., Place A., Ghanem L., et al. Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem. 274:1999;10140-10144.
34. Brar B.K., Stephanou A., Knight R.A., Latchman D.S. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol. 34:2002;483-492.
35. Chanalaris A., Sun Y., Latchman D.S., Stephanou A. SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol. 35:2003;257-264.
36. Yue T.L., Wang C., Gu J.L., Ma X.L., Kumar S., Lee J.C., et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 86:2000;692-699.
37. Yamashita K., Kajstura J., Discher D.J., Wasserlauf B.J., Bishopric N.H., Anversa P., et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res. 88:2001;609-614.
38. Ma X.L., Kumar S., Gao F., Louden C.S., Lopez B.L., Christopher T.A., et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 99:1999;1685-1691.
39. Mackay K., Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem. 274:1999;6272-6279.
40. Yaoita H., Ogawa K., Maehara K., Maruyama Y. Apoptosis in relevant clinical situations: contribution of apoptosis on myocardial infarction. Cardiovasc Res. 45:2000;630-641.
41. Bogoyevitch M.A. Signalling via stress-activated mitogen-activated protein kinases in the cardiovascular system. Cardiov Res. 45:2000;826-842.
42. Michel M.C., Li Y., Heusch G. Mitogen-activated protein kinases in the heart. Arch Pharmacol. 363:2001;245-266.
43. Sugden P.H., Bogoyevitch M.A. Intracellular signalling through protein kinases in the heart. Cardiov Res. 30:1995;478-492.
44. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912.
45. Mori M., Uchida M., Watanabe T., Kirito K., Hatake K., Ozawa K., et al. Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling. J Cell Physiol. 195:2003;290-297.
46. Erhardt P., Schremser E.J., Cooper G.M. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 19:1999;5308-5315.
47. Kulik G., Klippel A., Webber M.J. Antiapoptotic signalling by the IGF-1 receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17:1997;1595-1606.
48. Oh H., Fujio Y., Kunisada K., Hirota H., Matsui H., Kishimoto T., et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase in cardiac myocytes. J Biol Chem. 273:1998;9703-9710.
49. Sable C.L., Filippa N., Hemmings B., Van Obberghen E. cAMP stimulates protein kinase B in a Wortmannin-insensitive manner. FEBS Lett. 109:1997;253-257.
50. Kagawa T., Varticovski L., Sai Y., Arias I.M. Mechanism by which cAMP activates PI3-kinase and increases bile acid secretion in WIF-B9 cells. Am J Physiol Cell Physiol. 283:2002;C1655-C1666.
51. Rubio I., Rodriguez-Viciana P., Downward J., Wetzker R. Interaction of Ras with phosphoinositide 3-kinase &gamma. Biochem J. 326:1997;891-895.
52. Sharma G.-D., He J., Bazan E.P.H. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP-kinase cascades. J Biol Chem. 278:2003;21989-21997.
53. Railson J.E., Liao Z., Brar B.K., Buddle J.C., Pennica D., Stephanou A., et al. Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine. 17:2002;243-253.